Footnotes

• X @jeg_cworth

• Correction notice This paper has been amended since it was first published. The wrong competing interests statement was inadvertently added during the production stage.

• Contributors JEGC is the sole author.

• Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

• Competing interests JEGC is a sub-investigator on the Merck Sharp & Dohme (MSD, a subsidiary of Merck) sponsored MK-1654-004 and MK-1654-007 studies of clesrovimab, an investigational extended half-life monoclonal antibody towards RSV fusion protein. He has not nor has ever been employed or funded by Merck.

• Provenance and peer review Not commissioned; externally peer reviewed.

• Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.